COVID-19 Outlook: Variants, Boosters, And Being ‘Worse Off’ For Next Pathogens
Executive Summary
US FDA’s Peter Marks, Pfizer’s Mikael Dolsten and other experts discuss what is being done to prepare for the future, worries about higher fatality rates, and what 2023 might look like.